The study evaluated the effects of PIMPC, a metal-chelating imine GSK-3 inhibitor, on an Aβ/Cu2+-induced Alzheimer's disease rat model. Rats were treated with PIMPC and tested for levels of Aβ, tau, p-tau, and other markers. PIMPC was found to downregulate Aβ, tau, and p-tau expression levels and chelate copper and aluminum. Histological analysis showed PIMPC reduced cellular vacuoles and apoptosis in hippocampal cells compared to the Aβ/Cu2+ group. The results suggest PIMPC has multi-target effects for treating Alzheimer's disease by reducing pathogenic proteins and oxidative stress.